Birtamimab

DB16414InvestigationalProtein Based Therapies

Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).

Mechanism: Pharmacologically active on Immunoglobulin kappa light chain and Immunoglobulin lambda-1 light chain
Curator reviewed
Code names: ELT1-01 · HU2A4 · NEOD001

Resolves to

Compound

UNIIVXQ2SK8I3PCAS1608108-91-3

Targets

P0DOX7Immunoglobulin kappa light chainP0DOX8Immunoglobulin lambda-1 light chain

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Birtamimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account